|SERES THERAPEUTICS, INC. filed this Form 8-K on 10/16/2017|
SER-287 Phase 1b study endpoints
Primary Objectives Safety and tolerability Change in composition of intestinal microbiome at 8 weeks * Secondary Objectives Clinical remission, endoscopic improvement, and response through measure of the total modified Mayo Score Change in serum and
fecal biomarkers * Complement of microbiome metabolic pathways from stool, urine and blood * Immunological and pathologic changes in mucosal biopsies * * Microbiome data and other biomarker data are expected in the coming months
© Seres Therapeutics. All Rights Reserved.